#nvs
nvs
67 views
5 Discussing
Hot
Latest
🚨 STOCKS | Novartis Slides After Another Major Drug Failure
Novartis shares tumbled 8.8% in European trading today after another major setback in its drug pipeline.
The company’s experimental drug del-desiran failed to meet the primary endpoint in a Phase III trial for myotonic dystrophy.
Why this matters:
Novartis acquired the drug through its roughly $12B acquisition of Avidity, making it an important part of the company’s future growth story.
And this isn’t an isolated setback.
Just days earlier, another closely watched Novartis drug, pelacarsen, also failed a late-stage trial.
Two major pipeline disappointments in a matter of days are forcing investors to reassess how much future growth is already priced into the company.
Novartis is still maintaining its 5–6% annual sales growth target through 2030.
🇺🇸 U.S. ticker to watch today: $NVS
The key question now:
Will Wall Street treat this as a temporary pipeline setback — or start repricing Novartis’ long-term growth story?
#Stocks #NVS #Novartis #StockMarket #Biotech
Novartis shares tumbled 8.8% in European trading today after another major setback in its drug pipeline.
The company’s experimental drug del-desiran failed to meet the primary endpoint in a Phase III trial for myotonic dystrophy.
Why this matters:
Novartis acquired the drug through its roughly $12B acquisition of Avidity, making it an important part of the company’s future growth story.
And this isn’t an isolated setback.
Just days earlier, another closely watched Novartis drug, pelacarsen, also failed a late-stage trial.
Two major pipeline disappointments in a matter of days are forcing investors to reassess how much future growth is already priced into the company.
Novartis is still maintaining its 5–6% annual sales growth target through 2030.
🇺🇸 U.S. ticker to watch today: $NVS
The key question now:
Will Wall Street treat this as a temporary pipeline setback — or start repricing Novartis’ long-term growth story?
#Stocks #NVS #Novartis #StockMarket #Biotech
Log in to explore more content